Protalix BioTherapeutics
PLX
27 hedge funds and large institutions have $3.7M invested in Protalix BioTherapeutics in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 5 closing their positions.
798% more call options, than puts
Call options by funds: $988K | Put options by funds: $110K
185% more capital invested
Capital invested by funds: $1.3M → $3.7M (+$2.4M)
4.6% more ownership
Funds ownership: 2.54% → 7.13% (+4.6%)
10% less funds holding
Funds holding: 30 → 27 (-3)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$2.67M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$246K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$12.2K |
| 4 |
Renaissance Technologies
New York
|
+$2.66K |
| 5 |
ACA
Aptus Capital Advisors
Fairhope,
Alabama
|
+$1.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
-$162K |
| 2 |
Two Sigma Advisers
New York
|
-$53.6K |
| 3 |
VF
Virtu Financial
New York
|
-$31K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$27.7K |
| 5 |
Millennium Management
New York
|
-$21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FDCDDQ
26
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $260 | – | – | – |
|
|
SWM
27
Spire Wealth Management
Mclean,
Virginia
| – | -$162K | -148,800 | Closed |
|
|
VF
28
Virtu Financial
New York
| – | -$31K | -28,816 | Closed |
|
|
29
Millennium Management
New York
| – | -$21K | -19,223 | Closed |
|
30
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -800 | Closed |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$396 | +358 | +2,387% |
|
PLX Hedge Fund Activity: Q3 2022 in Review
27 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2022, worth a combined $3.7M — up 185% from $1.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PLX and 2 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $2.67M. The largest seller was Spire Wealth Management, exiting entirely with an estimated $162K sold.
- 27 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2022, down from 30 in Q2 2022.
- Funds reported $3.7M of Protalix BioTherapeutics stock for Q3 2022, up 185% quarter-over-quarter.
- 2 funds opened new Protalix BioTherapeutics positions in Q3 2022 and 5 closed out, a net change of -3 holders.
- The largest Protalix BioTherapeutics buyer in Q3 2022 was Highbridge Capital Management, an estimated $2.67M added.
- The largest Protalix BioTherapeutics seller in Q3 2022 was Spire Wealth Management, an estimated $162K sold.
Based on aggregated 13F filings for Q3 2022.